State Street
PLYX

State Street’s Polaryx Therapeutics Inc PLYX Stock Holding History

State Street’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Hold
58,104
– – ﹤0.01% 3887
2026
Q1 		$439K Buy
+58,104
New +$375K ﹤0.01% 3693

Other funds holding PLYX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

State Street's PLYX Position: Q2 2026 in Review

State Street held its Polaryx Therapeutics Inc (PLYX) position steady in Q2 2026 at 58,104 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #3887.

State Street first reported a position in PLYX in Q1 2026 and has held it in 2 quarters since. The position peaked at $439K in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

  • State Street held 58,104 shares of Polaryx Therapeutics Inc worth $155K as of Q2 2026.
  • State Street left its Polaryx Therapeutics Inc share count unchanged in Q2 2026.
  • Polaryx Therapeutics Inc made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3887 holding.
  • State Street first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 2 quarters since.
  • State Street's Polaryx Therapeutics Inc position peaked at $439K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.